Hospital
Valley Children's Hospital
Valley Children's Hospital was paid $22.84M by Medicaid between Jan 2018 and Dec 2024, across 299 billing codes. Its largest line is 99199, Unlisted special service, procedure or report — 24% of everything it billed.
33Billing provider infoVALLEY CHILDREN'S HOSPITAL
MADERA, CA 93636
MADERA, CA 93636
33aNPI1952312043assigned 08/11/2006
33bProvider typeChildren's Hospital
28Total paid$22.84M
24GClaims681,140
24DCodes billed299
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Children's Hospital providers in California
Rank by total paid#3 of 17
Median peer was paid$1.44M
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,229 | $2.93M | |
| 2019 | 123,954 | $3.73M | |
| 2020 | 73,556 | $2.38M | |
| 2021 | 82,846 | $3.16M | |
| 2022 | 98,297 | $3.62M | |
| 2023 | 97,288 | $3.64M | |
| 2024incomplete | 100,970 | $3.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99199 | Unlisted special service, procedure or report | 24% | 77,624 | 70,864 | $5.45M |
| 0450 | Emergency room services | 18% | 60,951 | 56,711 | $4.02M |
| 0510 | 7.4% | 32,186 | 30,640 | $1.68M | |
| 0760 | 4.7% | 26,911 | 25,912 | $1.08M | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.3% | 13,165 | 12,635 | $971K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.3% | 2,584 | 2,564 | $522K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.9% | 1,336 | 1,315 | $426K |
| 93975 | 1.7% | 1,721 | 1,643 | $381K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.4% | 4,946 | 4,735 | $324K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,425 | 1,389 | $319K |
| 0360 | 1.4% | 1,637 | 1,321 | $309K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 5,132 | 4,332 | $291K |
287 more codes
| 80053 | Comprehensive metabolic panel | 1.2% | 18,856 | $268K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 3,348 | $261K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 3,673 | $255K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 9,068 | $254K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 28,811 | $226K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,221 | $213K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,775 | $194K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,863 | $184K |
| 99221 | <1% | 6,284 | $180K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,690 | $178K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 601 | $167K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 540 | $166K |
| 93325 | <1% | 3,518 | $137K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,248 | $136K |
| 0761 | <1% | 5,735 | $127K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,613 | $127K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,632 | $123K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,917 | $119K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 3,533 | $114K |
| 81001 | <1% | 20,113 | $112K | |
| 76770 | <1% | 3,463 | $98K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,988 | $98K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 9,300 | $94K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,493 | $87K |
| 87505 | <1% | 594 | $87K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 797 | $86K |
| 87088 | <1% | 12,061 | $84K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 7,769 | $81K |
| 86140 | <1% | 9,422 | $73K | |
| G0378 | Hospital observation service, per hour | <1% | 1,329 | $70K |
| 0700 | <1% | 4,132 | $69K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,965 | $69K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 801 | $64K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,625 | $63K |
| 87631 | <1% | 662 | $60K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,526 | $57K |
| 74019 | <1% | 1,433 | $55K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 984 | $55K |
| 83690 | <1% | 4,383 | $54K | |
| 92557 | <1% | 1,809 | $51K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,763 | $51K |
| 87081 | <1% | 4,155 | $50K | |
| 74018 | <1% | 3,414 | $49K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,755 | $48K |
| 73610 | <1% | 2,354 | $47K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 690 | $46K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 524 | $43K |
| 76870 | <1% | 1,104 | $42K | |
| T1014 | Telehealth transmission, per minute, professional services bill separately | <1% | 4,456 | $41K |
| 73090 | <1% | 2,669 | $38K | |
| Q3014 | Telehealth originating site facility fee | <1% | 4,303 | $37K |
| 73630 | <1% | 2,037 | $36K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 880 | $36K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 724 | $35K |
| 87581 | <1% | 560 | $33K | |
| 82803 | <1% | 817 | $33K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,553 | $32K |
| 87486 | <1% | 541 | $31K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 956 | $31K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 343 | $31K |
| J3490 | Unclassified drugs | <1% | 7,334 | $30K |
| 92567 | <1% | 3,848 | $30K | |
| 76825 | <1% | 543 | $29K | |
| 76827 | <1% | 543 | $28K | |
| 87430 | <1% | 1,880 | $27K | |
| 84145 | <1% | 803 | $26K | |
| 92570 | <1% | 1,177 | $26K | |
| 0710 | <1% | 2,152 | $25K | |
| 73590 | <1% | 1,650 | $25K | |
| 82330 | <1% | 848 | $25K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 576 | $24K |
| 73130 | <1% | 1,333 | $24K | |
| 73070 | <1% | 2,458 | $24K | |
| 87040 | <1% | 1,336 | $23K | |
| 97139 | <1% | 7,343 | $22K | |
| 92523 | <1% | 1,302 | $22K | |
| 73140 | <1% | 2,126 | $20K | |
| 93304 | <1% | 1,375 | $20K | |
| 97750 | <1% | 2,243 | $20K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 428 | $20K |
| 73100 | <1% | 3,309 | $19K | |
| 94760 | <1% | 7,702 | $18K | |
| 72170 | <1% | 1,265 | $18K | |
| 92587 | <1% | 1,186 | $17K | |
| 95782 | <1% | 39 | $16K | |
| 83605 | <1% | 765 | $16K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,463 | $15K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,644 | $14K |
| 94060 | <1% | 1,092 | $14K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 52 | $14K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 61 | $13K |
| 73000 | <1% | 1,055 | $13K | |
| 85651 | <1% | 4,191 | $13K | |
| 29075 | <1% | 820 | $13K | |
| 76536 | <1% | 373 | $13K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 661 | $12K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 171 | $12K |
| 85730 | <1% | 1,567 | $12K | |
| 76801 | <1% | 319 | $11K | |
| 94010 | <1% | 1,692 | $11K | |
| 94644 | <1% | 490 | $11K | |
| 92700 | <1% | 1,163 | $11K | |
| 85007 | <1% | 2,750 | $10K | |
| 73110 | <1% | 589 | $10K | |
| 97802 | <1% | 830 | $10K | |
| 92552 | <1% | 955 | $10K | |
| 84439 | <1% | 2,562 | $10K | |
| 0270 | <1% | 1,880 | $10K | |
| 95819 | <1% | 887 | $10K | |
| 73562 | <1% | 471 | $9K | |
| 76813 | <1% | 238 | $9K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,280 | $9K |
| 93321 | <1% | 1,391 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,559 | $9K |
| 77077 | <1% | 958 | $8K | |
| 92522 | <1% | 375 | $8K | |
| 85610 | <1% | 2,078 | $8K | |
| 70360 | <1% | 1,343 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 837 | $8K |
| 82728 | <1% | 1,928 | $8K | |
| 84703 | <1% | 4,294 | $8K | |
| 97799 | <1% | 4,279 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 339 | $8K |
| 72082 | <1% | 628 | $8K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 131 | $8K |
| 82947 | <1% | 1,535 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,421 | $7K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 784 | $7K |
| 0369 | <1% | 15 | $7K | |
| 97165 | <1% | 838 | $7K | |
| 87507 | <1% | 14 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 834 | $7K |
| 97803 | <1% | 668 | $7K | |
| 73080 | <1% | 280 | $7K | |
| 73560 | <1% | 406 | $6K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 841 | $6K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 245 | $6K |
| 82784 | <1% | 2,200 | $6K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,546 | $5K |
| 94664 | <1% | 1,379 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 571 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 469 | $5K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 989 | $5K |
| 86635 | <1% | 334 | $4K | |
| 92555 | <1% | 1,120 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,177 | $4K |
| 70220 | <1% | 351 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 172 | $4K |
| 84132 | <1% | 839 | $4K | |
| 84295 | <1% | 800 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,400 | $4K |
| 83735 | <1% | 473 | $4K | |
| 94375 | <1% | 640 | $4K | |
| 80069 | <1% | 1,109 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,490 | $3K |
| 80061 | Lipid panel | <1% | 1,466 | $3K |
| 76821 | <1% | 370 | $3K | |
| 73620 | <1% | 171 | $3K | |
| 76820 | <1% | 629 | $3K | |
| 84466 | <1% | 511 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 155 | $3K |
| 82785 | <1% | 405 | $3K | |
| 76010 | <1% | 68 | $3K | |
| 73564 | <1% | 150 | $3K | |
| 85014 | <1% | 835 | $2K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 2,362 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 266 | $2K |
| 97010 | <1% | 207 | $2K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 800 | $2K |
| A4217 | Sterile water/saline, 500 ml | <1% | 306 | $2K |
| 87077 | <1% | 1,861 | $2K | |
| 82550 | <1% | 288 | $2K | |
| 83615 | <1% | 439 | $2K | |
| 82570 | <1% | 1,234 | $2K | |
| 87186 | <1% | 1,807 | $2K | |
| 82977 | <1% | 526 | $2K | |
| 85246 | <1% | 146 | $2K | |
| 84484 | <1% | 107 | $2K | |
| 85397 | <1% | 146 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 70 | $2K |
| 95816 | <1% | 25 | $2K | |
| 74455 | <1% | 96 | $2K | |
| 83540 | <1% | 576 | $2K | |
| 85240 | <1% | 160 | $2K | |
| 83516 | <1% | 1,256 | $1K | |
| 88304 | <1% | 80 | $1K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 226 | $1K |
| 95012 | <1% | 224 | $1K | |
| 86171 | <1% | 294 | $1K | |
| 94645 | <1% | 78 | $1K | |
| 85045 | <1% | 636 | $1K | |
| 87420 | <1% | 87 | $1K | |
| 91065 | <1% | 362 | $1K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 44 | $1K |
| 92579 | <1% | 78 | $1K | |
| 86308 | <1% | 109 | $1K | |
| 84100 | <1% | 261 | $1K | |
| 86850 | <1% | 72 | $1K | |
| 73030 | <1% | 42 | $1K | |
| 92521 | <1% | 55 | $1K | |
| 85027 | <1% | 627 | $1K | |
| 86160 | <1% | 176 | $902.39 | |
| 84156 | <1% | 898 | $868.95 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 828 | $856.85 |
| 93320 | <1% | 57 | $813.99 | |
| 73060 | <1% | 52 | $783.06 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 918 | $757.75 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 161 | $747.34 |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 530 | $706.32 |
| 86003 | <1% | 557 | $681.83 | |
| 87046 | <1% | 209 | $679.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,078 | $667.56 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 117 | $662.82 |
| 84550 | <1% | 205 | $657.81 | |
| 73600 | <1% | 19 | $628.87 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 117 | $618.02 |
| 73552 | <1% | 31 | $591.72 | |
| 69210 | <1% | 206 | $569.48 | |
| 86038 | <1% | 334 | $556.22 | |
| 86901 | <1% | 136 | $554.84 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 70 | $499.29 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,715 | $435.09 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 76 | $433.27 |
| 93308 | <1% | 13 | $403.68 | |
| 77072 | <1% | 96 | $392.74 | |
| 96379 | <1% | 965 | $385.56 | |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml | <1% | 62 | $372.88 |
| 86900 | <1% | 136 | $364.10 | |
| 59025 | Fetal non-stress test | <1% | 32 | $342.50 |
| 80076 | <1% | 175 | $316.34 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $293.20 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26 | $293.20 |
| 85390 | <1% | 96 | $291.87 | |
| 83993 | <1% | 56 | $289.85 | |
| 97166 | <1% | 71 | $275.44 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 26 | $259.08 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $254.00 |
| 82150 | <1% | 31 | $231.54 | |
| 73660 | <1% | 15 | $209.20 | |
| 82248 | <1% | 53 | $182.30 | |
| 87070 | <1% | 27 | $173.66 | |
| 99205 | Prolong outpt/office vis | <1% | 32 | $171.20 |
| 86331 | <1% | 24 | $164.15 | |
| 87660 | <1% | 13 | $150.72 | |
| 84520 | <1% | 27 | $136.00 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 13 | $132.43 |
| 84702 | <1% | 64 | $121.23 | |
| 84436 | <1% | 41 | $114.31 | |
| 86376 | <1% | 69 | $113.10 | |
| 82247 | <1% | 17 | $92.24 | |
| 93226 | <1% | 12 | $91.41 | |
| 86800 | <1% | 49 | $85.75 | |
| 86255 | <1% | 70 | $81.66 | |
| 82565 | <1% | 12 | $70.64 | |
| 93225 | <1% | 12 | $69.89 | |
| 99201 | <1% | 12 | $60.00 | |
| 92550 | <1% | 16 | $56.37 | |
| V5008 | Hearing screening | <1% | 26 | $50.60 |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 162 | $45.58 |
| 96127 | <1% | 520 | $43.39 | |
| 92556 | <1% | 24 | $41.24 | |
| 99173 | <1% | 665 | $25.80 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 14 | $19.52 |
| 83655 | <1% | 65 | $17.50 | |
| 86225 | <1% | 12 | $16.00 | |
| 0636 | <1% | 1,649 | $15.08 | |
| A4322 | Irrigation syringe, bulb or piston, each | <1% | 109 | $9.12 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,555 | $2.24 |
| A4649 | Surgical supply; miscellaneous | 0% | 3,160 | $0.00 |
| 29799 | 0% | 99 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 12 | $0.00 |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 0% | 248 | $0.00 |
| 84305 | 0% | 15 | $0.00 | |
| 0272 | 0% | 41 | $0.00 | |
| 29065 | 0% | 225 | $0.00 | |
| 94762 | 0% | 637 | $0.00 | |
| 0271 | 0% | 611 | $0.00 | |
| 96040 | 0% | 104 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 292 | $0.00 |
| 90686 | 0% | 208 | $0.00 | |
| 99070 | 0% | 251 | $0.00 | |
| B4160 | Enteral formula, for pediatrics, nutritionally complete calorically dense (equal to or greater than 0.7 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit | 0% | 40 | $0.00 |
| B9998 | Noc for enteral supplies | 0% | 45 | $0.00 |
| G0155 | Services of clinical social worker in home health or hospice settings, each 15 minutes | 0% | 14 | $0.00 |
| 97804 | 0% | 17 | $0.00 | |
| 0370 | 0% | 13 | $0.00 | |
| 80349 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMYCROFT, TINA (SENIOR VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Valley Children's Hospital | Madera, CA | $107.11M |
| Valley Children's Hospital | Fresno, CA | $20.85M |
| Valley Children's Hospital | Madera, CA | $14.28M |
| ST Jude Hospital Yorba Linda | Santa Rosa, CA | $10.59M |
| Valley Children's Hospital | Madera, CA | $262K |
| Valley Children's Hospital | Fresno, CA | $53K |
| King County Public Hospital District No. 2 | Kirkland, WA | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.